WNT signaling in lung disease: A failure or a regeneration signal?

American Journal of Respiratory Cell and Molecular Biology

Volumn 42, Issue 1, 2010, Pages 21-31

  Königshoff, Melanie ^a   Eickelberg, Oliver ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

catenin; Epithelial cell; Epithelial to mesenchymal transition; Lung cancer; Lung fibrosis

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FIBROBLAST GROWTH FACTOR; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NOTCH RECEPTOR; PROTEIN DERIVATIVE; PROTEIN DKK; PROTEIN INHIBITOR; PROTEIN WISE; PROTEN KREMEN 1; PROTEN KREMEN 2; R SPONDIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN; WNT1 PROTEIN; WNT2 PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN;

CANCER INVASION; CELL ACTIVATION; CELL ADHESION; CELL FUNCTION; CELL PROLIFERATION; CELL RENEWAL; CELL TYPE; EMBRYO DEVELOPMENT; EPITHELIUM CELL; FIBROGENESIS; HOMEOSTASIS; HUMAN; LIGAND BINDING; LUNG CANCER; LUNG CARCINOGENESIS; LUNG DEVELOPMENT; LUNG DISEASE; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; MORPHOGENESIS; NONHUMAN; PATHOGENESIS; PLASTICITY; PLEIOTROPY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; ANIMAL; BIOLOGICAL MODEL; EPITHELIUM; FIBROSIS; LUNG; LUNG TUMOR; MESODERM; METABOLISM; PATHOLOGY; REGENERATION;

ANIMALS; BETA CATENIN; EPITHELIAL CELLS; EPITHELIUM; FIBROSIS; HUMANS; LUNG; LUNG DISEASES; LUNG NEOPLASMS; MESODERM; MODELS, BIOLOGICAL; PULMONARY FIBROSIS; REGENERATION; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 73949090577     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0485TR     Document Type: Review

References (182)

1. Logan CY, Nusse R. The WNT signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
2. Dale TC. Signal transduction by the WNT family of ligands. Biochem J 1998;329:209-223.
3. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat Rev Genet 2004;5:691-701.
4. Cadigan KM, Liu YI. WNT signaling: complexity at the surface. J Cell Sci 2006;119:395-402.
5. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (INT-1) on mouse chromosome 15. Nature 1984;307:131-136.
6. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99-109.
7. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980;287:795-801.
8. Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R. The Drosophila homolog of the mouse mammary oncogene INT-1 is identical to the segment polarity gene wingless. Cell 1987;50:649-657.
9. Nusse R, Brown A, Papkoff J, Scambler P, Shackleford G, McMahon A, Moon R, Varmus H. A new nomenclature for INT -1 and related genes: the WNT gene family. Cell 1991;64:231.
10. Mikels AJ, Nusse R. WNTs as ligands: processing, secretion and reception. Oncogene 2006;25:7461-7468.
11. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR III, Nusse R. WNT proteins are lipid-modified and can act as stem cell growth factors. Nature 2003;423:448-452.
12. Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of WNT proteins and their receptors. Cell Signal 2007;19:659-671.
13. Gordon MD, Nusse R. WNT signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-22433.
14. Hendrickx M, Leyns L. Non-conventional frizzled ligands and WNT receptors. Dev Growth Differ 2008;50:229-243.
15. MacDonald BT, Yokota C, Tamai K, Zeng X, He X. WNT signal amplification via activity, cooperativity, and regulation of multiple intracellular pppsp motifs in the WNT co-receptor LRP6. J Biol Chem 2008;283:16115-16123.
16. Nusse R. WNT targets: repression and activation. Trends Genet 1999;15:1-3.
17. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of WNT signaling through beta-catenin. Science 2002;296:1644-1646.
18. Vlad A, Rohrs S, Klein-Hitpass L, Muller O. The first five years of the WNT targetome. Cell Signal 2008;20:795-802.
19. Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, Sugano S, Akiyama T. DKK 1, a negative regulator of WNT signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004;23:8520-8526.
20. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, et al. Elevated expression of axin2 and hNKd mRNA provides evidence that WNT/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 2001;98:14973-14978.
21. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-myc as a target of the APC pathway. Science 1998;281:1509-1512.
22. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin d1 in colon carcinoma cells. Nature 1999;398:422-426.
23. Kawano Y, Kypta R. Secreted antagonists of the WNT signalling pathway. J Cell Sci 2003;116:2627-2634.
24. Shi Y, He B, You L, Jablons DM. Roles of secreted frizzled-related proteins in cancer. Acta Pharmacol Sin 2007;28:1499-1504.
25. Niehrs C. Function and biological roles of the Dickkopf family of WNT modulators. Oncogene 2006;25:7469-7481.
26. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond WNT inhibition: new functions of secreted frizzled-related proteins in development and disease. J Cell Sci 2008;121:737-746.
27. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J. A new secreted protein that binds to WNT proteins and inhibits their activities. Nature 1999;398:431-436.
28. Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. Wise, a context-dependent activator and inhibitor of WNT signalling. Development 2003;130:4295-4305.
29. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391:357-362.
30. Wu W, Glinka A, Delius H, Niehrs C. Mutual antagonism between Dickkopf 1 and Dickkopf 2 regulates WNT/beta-catenin signalling. Curr Biol 2000;10:1611-1614.
31. Mao B, Niehrs C. Kremen2 modulates Dickkopf 2 activity during WNT/LRP6 signaling. Gene 2003;302:179-183.
32. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, et al. Kremen proteins are Dickkopf receptors that regulate WNT/beta-catenin signalling. Nature 2002;417:664-667.
33. Nakamura T, Nakamura T, Matsumoto K. The functions and possible significance of Kremen as the gatekeeper of WNT signalling in development and pathology. J Cell Mol Med 2008;12:391-408.
34. Wang K, Zhang Y, Li X, Chen L, Wang H, Wu J, Zheng J, Wu D. Characterization of the Kremen-binding site on DKK1 and elucidation of the role of Kremen in DKK-mediated WNT antagonism. J Biol Chem 2008;283:23371-23375.
35. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of WNT signalling inhibition mediated by Dickkopf-1 interaction with LRP6/arrow. Nat Cell Biol 2001;3:683-686.
36. Brott BK, Sokol SY. Regulation of WNT/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 2002;22:6100-6110.
37. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-325.
38. Kim KA, Wagle M, Tran K, Zhan X, Dixon MA, Liu S, Gros D, Korver W, Yonkovich S, Tomasevic N, et al. R-spondin family members regulate the WNT pathway by a common mechanism. Mol Biol Cell 2008;19:2588-2596.
39. Nam JS, Turcotte TJ, Yoon JK. Dynamic expression of R-spondin family genes in mouse development. Gene Expr Patterns 2007;7:306-312.
40. Mercurio S, Latinkic B, Itasaki N, Krumlauf R, Smith JC. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 2004;131:2137-2147.
41. Sato M. Upregulation of the WNT/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. Acta Derm Venereol 2006;86:300-307.
42. Hing HK, Sun X, Artavanis-Tsakonas S. Modulation of wingless signaling by notch in Drosophila. Mech Dev 1994;47:261-268.
43. Warburton D, Bellusci S, De Langhe S, Del Moral PM, Fleury V, Mailleux A, Tefft D, Unbekandt M, Wang K, Shi W. Molecular mechanisms of early lung specification and branching morphogenesis. Pediatr Res 2005;57:26R-37R.
44. Reddy S, Andl T, Bagasra A, Lu MM, Epstein DJ, Morrisey EE, Millar SE. Characterization of WNT gene expression in developing and postnatal hair follicles and identification of WNT5a as a target of sonic hedgehog in hair follicle morphogenesis. Mech Dev 2001;107:69-82.
45. Watt FM. Unexpected hedgehog-WNT interactions in epithelial differentiation. Trends Mol Med 2004;10:577-580.
46. Gavin BJ, McMahon JA, McMahon AP. Expression of multiple novel WNT-1/INT-1-related genes during fetal and adult mouse development. Genes Dev 1990;4:2319-2332.
47. Cardoso WV, Lu J. Regulation of early lung morphogenesis: questions, facts and controversies. Development 2006;133:1611-1624.
48. Shannon JM, Hyatt BA. Epithelial-mesenchymal interactions in the developing lung. Annu Rev Physiol 2004;66:625-645.
49. Hogan BL, Yingling JM. Epithelial/mesenchymal interactions and branching morphogenesis of the lung. Curr Opin Genet Dev 1998;8:481-486.
50. Okubo T, Hogan BL. Hyperactive WNT signaling changes the developmental potential of embryonic lung endoderm. J Biol 2004;3:11.
51. Levay-Young BK, Navre M. Growth and developmental regulation of WNT-2 (IRP) gene in mesenchymal cells of fetal lung. Am J Physiol 1992;262:L672-L683.
52. Shu W, Jiang YQ, Lu MM, Morrisey EE. WNT7b regulates mesenchymal proliferation and vascular development in the lung. Development 2002;129:4831-4842.
53. Li C, Xiao J, Hormi K, Borok Z, Minoo P. WNT5a participates in distal lung morphogenesis. Dev Biol 2002;248:68-81.
54. Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ. Targeted disruption of the WNT2 gene results in placentation defects. Development 1996;122:3343-3353.
55. Zakin LD, Mazan S, Maury M, Martin N, Guenet JL, Brulet P. Structure and expression of WNT13, a novel mouse WNT2 related gene. Mech Dev 1998;73:107-116.
56. Wang Z, Shu W, Lu MM, Morrisey EE. WNT7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with FZD1, FZD10, and LRP5. Mol Cell Biol 2005;25:5022-5030.
57. Rajagopal J, Carroll TJ, Guseh JS, Bores SA, Blank LJ, Anderson WJ, Yu J, Zhou Q, McMahon AP, Melton DA. WNT7b stimulates embryonic lung growth by coordinately increasing the replication of epithelium and mesenchyme. Development 2008;135:1625-1634.
58. Li C, Hu L, Xiao J, Chen H, Li JT, Bellusci S, Delanghe S, Minoo P. WNT5a regulates SHH and FGF10 signaling during lung development. Dev Biol 2005;287:86-97.
59. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin D, Bressan GM, Piccolo S. Mapping WNT/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 2003;100:3299-3304.
60. Shu W, Guttentag S, Wang Z, Andl T, Ballard P, Lu MM, Piccolo S, Birchmeier W, Whitsett JA, Millar SE, et al. WNT/beta-catenin signaling acts upstream of n-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol 2005;283:226-239.
61. Mucenski ML, Nation JM, Thitoff AR, Besnard V, Xu Y, Wert SE, Harada N, Taketo MM, Stahlman MT, Whitsett JA. Beta-catenin regulates differentiation of respiratory epithelial cells in vivo. Am J Physiol 2005;289:L971-L979.
62. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, Birchmeier W, Morrisey EE, Whitsett JA. Beta-catenin is required for specification of proximal/distal cell fate during lung morphogenesis. J Biol Chem 2003;278:40231-40238.
63. Dean CH, Miller LA, Smith AN, Dufort D, Lang RA, Niswander LA. Canonical WNT signaling negatively regulates branching morphogenesis of the lung and lacrimal gland. Dev Biol 2005;286:270-286.
64. De Langhe SP, Sala FG, Del Moral PM, Fairbanks TJ, Yamada KM, Warburton D, Burns RC, Bellusci S. Dickkopf-1 (DKK1) reveals that fibronectin is a major target of WNT signaling in branching morphogenesis of the mouse embryonic lung. Dev Biol 2005;277:316-331.
65. Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, Seeger W, Eickelberg O. Functional WNT signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008;3:e2142.
66. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, et al. Restoration of WNT-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem 2005;280:19625-19634.
67. Paul S, Dey A. WNT signaling and cancer development: therapeutic implication. Neoplasma 2008;55:165-176.
68. Nusse R. WNT signaling in disease and in development. Cell Res 2005;15:28-32.
69. He B, Jablons DM. WNT signaling in stem cells and lung cancer. Ernst Schering Found Symp Proc 2006;(5):27-58.
70. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-343.
71. Van Scoyk M, Randall J, Sergew A, Williams LM, Tennis M, Winn RA. WNT signaling pathway and lung disease. Transl Res 2008;151:175-180.
72. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M, Drabkin HA. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001;85:64-68.
73. Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurrer MO. APC mutations are infrequent but present in human lung cancer. Cancer Lett 2004;207:197-203.
74. Mazieres J, He B, You L, Xu Z, Jablons DM. WNT signaling in lung cancer. Cancer Lett 2005;222:1-10.
75. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against WNT-1 induces apoptosis in human cancer cells. Neoplasia 2004;6:7-14.
76. Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY. WNT-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 2001;152:87-96.
77. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, et al. Inhibition of WNT-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 2004;23:6170-6174.
78. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M. WNT5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor: an expression in non-small-cell lung cancer. J Clin Oncol 2005;23:8765-8773.
79. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA. Antitumorigenic effect of WNT 7a and FZD 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2006;281:26943-26950.
80. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the WNT pathway in non small cell lung cancer: evidence of Dishevelled overexpression. Oncogene 2003;22:7218-7221.
81. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B, Jablons D. WNT inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 2007;133:733-737.
82. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. WNT inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-4720.
83. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, et al. Wif1, a component of the WNT pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-212.
84. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, Zhang L. Downregulation of DKK3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008;29:84-92.
85. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM. Expression of the secreted Frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004;23:6672-6676.
86. Tang M, Torres-Lanzas J, Lopez-Rios F, Esteller M, Sanchez-Cespedes M. WNT signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer 2006;119:2603-2606.
87. Retera JM, Leers MP, Sulzer MA, Theunissen PH. The expression of beta-catenin in non-small-cell lung cancer: A clinicopathological study. J Clin Pathol 1998;51:891-894.
88. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789-4796.
89. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001;54:391-395.
90. Hommura F, Furuuchi K, Yamazaki K, Ogura S, Kinoshita I, Shimizu M, Moriuchi T, Katoh H, Nishimura M, Dosaka-Akita H. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer 2002;94:752-758.
91. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008;5:e62.
92. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-967.
93. Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006;3:330-338.
94. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
95. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
96. Chapman HA. Disorders of lung matrix remodeling. J Clin Invest 2004;113:148-157.
97. Horowitz JC, Thannickal VJ. Epithelial-mesenchymal interactions in pulmonary fibrosis. Semin Respir Crit Care Med 2006;27:600-612.
98. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005;128(5 Suppl 1)526S-532S.
99. Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3:322-329.
100. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med 2006;27(1 Suppl 1)S11-S16.
101. Kaminski N, Rosas IO. Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes? Proc Am Thorac Soc 2006;3:339-344.
102. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006;173:188-198.
103. Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007;175:45-54.
104. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-6297.
105. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005;2:e251.
106. Lewis CC, Yang JY, Huang X, Banerjee SK, Blackburn MR, Baluk P, McDonald DM, Blackwell TS, Nagabhushanam V, Peters W, et al. Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med 2008;177:376-387.
107. Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119:772-787.
108. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et al. Aberrant WNT/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003;162:1495-1502.
109. Morrisey EE. WNT signaling and pulmonary fibrosis. Am J Pathol 2003;162:1393-1397.
110. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs C. WNT induces injury and promotes Dishevelled-dependent LRP6 phosphorylation. Science 2007;316:1619-1622.
111. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007;64:1930-1944.
112. Douglas IS, Diaz del Valle F, Winn RA, Voelkel NF. Beta-catenin in the fibroproliferative response to acute lung injury. Am J Respir Cell Mol Biol 2006;34:274-285.
113. Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson DA. Expression and function of Wingless and Frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97:2791-2796.
114. Coon DR, Roberts DJ, Loscertales M, Kradin R. Differential epithelial expression of SHH and FOXf1 in usual and nonspecific interstitial pneumonia. Exp Mol Pathol 2006;80:119-123.
115. Stewart GA, Hoyne GF, Ahmad SA, Jarman E, Wallace WA, Harrison DJ, Haslett C, Lamb JR, Howie SE. Expression of the developmental sonic hedgehog (SHH) signalling pathway is up-regulated in chronic lung fibrosis and the SHH receptor Patched 1 is present in circulating T lymphocytes. J Pathol 2003;199:488-495.
116. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S)13S-24S.
117. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45:173-202.
118. Laumanns IP, Fink L, Wilhelm J, Wolff JC, Mitnacht-Kraus R, Graef-Hoechst S, Stein MM, Bohle RM, Klepetko W, Hoda MA, et al. The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2009;40:683-691.
119. Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol 2007;293:L1-L8.
120. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-564.
121. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol 2009;184:83-99.
122. Mason RJ. Biology of alveolar type II cells. Respirology 2006;11:S12-S15.
123. Matthay MA, Robriquet L, Fang X. Alveolar epithelium: role in lung fluid balance and acute lung injury. Proc Am Thorac Soc 2005;2:206-213.
124. Dobbs LG, Johnson MD. Alveolar epithelial transport in the adult lung. Respir Physiol Neurobiol 2007;159:283-300.
125. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
126. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-746.
127. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
128. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-558.
129. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol 2006;35:3-9.
130. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Med 2008;25:685-693.
131. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002;26:463-476.
132. Kato N, Shimmura S, Kawakita T, Miyashita H, Ogawa Y, Yoshida S, Higa K, Okano H, Tsubota K. Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci 2007;48:1511-1517.
133. Dissanayake SK, Wade MS, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, et al. The WNT5a/PKC pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors, and initiation of an epithelial to mesenchymal transition. J Biol Chem 2007;282:17259-17271.
134. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol 2007;293:L525-L534.
135. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006;103:13180-13185.
136. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005;166:1321-1332.
137. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005;6:56.
138. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009;119:213-224.
139. Benjamin JM, Nelson WJ. Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol 2008;18:53-64.
140. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996;61:514-523.
141. Gottardi CJ, Gumbiner BM. Adhesion signaling: how beta-catenin interacts with its partners. Curr Biol 2001;11:R792-R794.
142. Nelson WJ, Nusse R. Convergence of WNT, beta-catenin, and cadherin pathways. Science 2004;303:1483-1487.
143. Harris TJ, Peifer M. Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol 2005;15:234-237.
144. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and WNT signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006;16:51-59.
145. Gottardi CJ, Gumbiner BM. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 2004;167:339-349.
146. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W. Essential role of bcl9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev 2004;18:2225-2230.
147. Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell 2006;11:601-612.
148. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, et al. WNT7a induces Ecadherin in lung cancer cells. Proc Natl Acad Sci USA 2003;100:10429-10434.
149. Thannickal VJ, Toews GB, White ES, Lynch JP III, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004;55:395-417.
150. Chilosi M, Poletti V, Murer B, Lestani M, Cancellieri A, Montagna L, Piccoli P, Cangi G, Semenzato G, Doglioni C. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltan-p63. Lab Invest 2002;82:1335-1345.
151. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996;11:463-483.
152. Qunn L, Takemura T, Ikushima S, Ando T, Yanagawa T, Akiyama O, Oritsu M, Tanaka N, Kuroki T. Hyperplastic epithelial foci in honeycomb lesions in idiopathic pulmonary fibrosis. Virchows Arch 2002;441:271-278.
153. Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med 2001;7:278-282.
154. Sharma OP, Lamb C. Cancer in interstitial pulmonary fibrosis and sarcoidosis. Curr Opin Pulm Med 2003;9:398-401.
155. Samet JM. Does idiopathic pulmonary fibrosis increase lung cancer risk? Am J Respir Crit Care Med 2000;161:1-2.
156. Micke P, Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005;9:1217-1233.
157. Phan SH. Fibroblast phenotypes in pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29(3 Suppl)S87-S92.
158. Klapholz-Brown Z, Walmsley GG, Nusse YM, Nusse R, Brown PO. Transcriptional program induced by WNT protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments. PLoS One 2007;2:e945.
159. Boucherat O, Franco-Montoya ML, Thibault C, Incitti R, Chailley-Heu B, Delacourt C, Bourbon JR. Gene expression profiling in lung fibroblasts reveals new players in alveolarization. Physiol Genomics 2007;32:128-141.
160. Chen S, McLean S, Carter DE, Leask A. The gene expression profile induced by WNT 3a in NIH 3T3 fibroblasts. J Cell Commun Signal 2007;1:175-183.
161. Reya T, Clevers H. WNT signalling in stem cells and cancer. Nature 2005;434:843-850.
162. Kleber M, Sommer L. WNT signaling and the regulation of stem cell function. Curr Opin Cell Biol 2004;16:681-687.
163. Hong KU, Reynolds SD, Watkins S, Fuchs E, Stripp BR. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol 2004;164:577-588.
164. Giangreco A, Reynolds SD, Stripp BR. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 2002;161:173-182.
165. Stripp BR, Shapiro SD. Stem cells in lung disease, repair, and the potential for therapeutic interventions: State-of-the-art and future challenges. Am J Respir Cell Mol Biol 2006;34:517-518.
166. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-835.
167. Stripp BR, Reynolds SD. Maintenance and repair of the bronchiolar epithelium. Proc Am Thorac Soc 2008;5:328-333.
168. Zhang Y, Goss AM, Cohen ED, Kadzik R, Lepore JJ, Muthukumaraswamy K, Yang J, DeMayo FJ, Whitsett JA, Parmacek MS, et al. A GATA6-WNT pathway required for epithelial stem cell development and airway regeneration. Nat Genet 2008;40:862-870.
169. Reynolds SD, Zemke AC, Giangreco A, Brockway BL, Teisanu RM, Drake JA, Mariani T, Di PY, Taketo MM, Stripp BR. Conditional stabilization of beta-catenin expands the pool of lung stem cells. Stem Cells 2008;26:1337-1346.
170. Borok Z, Li C, Liebler J, Aghamohammadi N, Londhe VA, Minoo P. Developmental pathways and specification of intrapulmonary stem cells. Pediatr Res 2006;59:84R-93R.
171. Zemke AC, Teisanu RM, Giangreco A, Drake JA, Brockway BL, Reynolds SD, Stripp BR. β-catenin is not necessary for maintenance or repair of the bronchiolar epithelium. Am J Respir Cell Mol Biol (In press).
172. Warburton D, Perin L, Defilippo R, Bellusci S, Shi W, Driscoll B. Stem/progenitor cells in lung development, injury repair, and regeneration. Proc Am Thorac Soc 2008;5:703-706.
173. Loebinger MR, Sage EK, Janes SM. Mesenchymal stem cells as vectors for lung disease. Proc Am Thorac Soc 2008;5:711-716.
174. Etheridge SL, Spencer GJ, Heath DJ, Genever PG. Expression profiling and functional analysis of WNT signaling mechanisms in mesenchymal stem cells. Stem Cells 2004;22:849-860.
175. Mohr A, Lyons M, Deedigan L, Harte T, Shaw G, Howard L, Barry F, O'Brien T, Zwacka R. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008;12:2628-2643.
176. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-563.
177. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham KL. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33:145-152.
178. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407-8411.
179. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004;113:243-252.
180. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-446.
181. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007;353:104-108.
182. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, Wang Z, Liao H, Toews GB, Krebsbach PH, et al. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest 2007;117:989-996.